Literature DB >> 25248590

Cushing's disease.

Nicholas A Tritos1, Beverly M K Biller2.   

Abstract

Cushing's disease (CD) is caused by a pituitary tumor secreting corticotropin (ACTH), leading to cortisol excess. Patients with CD comprise approximately 70% of patients with endogenous Cushing's syndrome (CS). If the diagnosis and treatment are delayed, patients with CD may suffer the deleterious consequences of hypercortisolism, leading to significant morbidity and mortality. The diagnosis of CD is complex and includes two separate steps: establishing the presence of pathologic hypercortisolism and identifying the underlying cause. The management of CD usually includes transsphenoidal pituitary surgery (TSS) as the primary form of therapy. Pituitary surgery by the most experienced surgeons leads to remission of CD in 70-90% of patients. Recurrence of CD may occur in up to 25% of patients on long-term follow-up. Patients with recurrent CD may be treated with repeat TSS, radiation therapy to the pituitary with interim medical therapy (including steroidogenesis inhibitors, centrally acting agents or a glucocorticoid receptor antagonist) or bilateral adrenalectomy. Improvements in diagnosis and management of CD have led to higher patient survival. However, quality of life is impaired on long-term follow-up in some patients, even those in remission. Better understanding of the pathogenesis of CD may lead to the development of more effective therapies.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cushing's disease; cabergoline; ketoconazole; metyrapone; mifepristone; mitotane; pasireotide; pituitary adenoma; radiation therapy; transsphenoidal surgery

Mesh:

Substances:

Year:  2014        PMID: 25248590     DOI: 10.1016/B978-0-444-59602-4.00015-0

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  10 in total

1.  Medical combination therapies in Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Márcio C Machado; Marcello D Bronstein
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

2.  Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.

Authors:  Megan McGrath; Celena Ma; Douglas E Raines
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

3.  Screening for GPR101 defects in pediatric pituitary corticotropinomas.

Authors:  Giampaolo Trivellin; Ricardo R Correa; Maria Batsis; Fabio R Faucz; Prashant Chittiboina; Ivana Bjelobaba; Darwin O Larco; Martha Quezado; Adrian F Daly; Stanko S Stojilkovic; T John Wu; Albert Beckers; Maya Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2016-06-01       Impact factor: 5.678

Review 4.  Update on radiation therapy in patients with Cushing's disease.

Authors:  Nicholas A Tritos; Beverly M K Biller
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

5.  Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical center and a literature review.

Authors:  Jianyu Zhu; Lin Lu; Yong Yao; Shi Chen; Wei Li; Hui You; Feng Feng; Ming Feng; Yi Zhang; Zhicheng Wang; Xu Sun; Xiaoxu Li; Huijuan Zhu; Renzhi Wang; Zhaolin Lu
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

6.  Geographic-Related Differences of Pituitary Adenomas Hormone Profile: Analysis of Two Groups Coming from Southeastern and Eastern Europe.

Authors:  Anca Maria Cimpean; Eugen Melnic; Bogdan Bălinişteanu; Ana Corlan; Mihail Coculescu; Sergiu Rusu; Marius Raica
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

7.  Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis.

Authors:  Nairui Zhao; Xinxin Yang; Cuiliu Li; Jie Ma; Xiuping Yin
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

8.  Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing's disease.

Authors:  Jon Ramm-Pettersen; Helene Halvorsen; Johan Arild Evang; Pål Rønning; Per Kristian Hol; Jens Bollerslev; Jon Berg-Johnsen; Eirik Helseth
Journal:  BMC Endocr Disord       Date:  2015-10-25       Impact factor: 2.763

9.  The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study.

Authors:  Lucio Vilar; José Luciano Albuquerque; Ruy Lyra; Erik Trovão Diniz; Frederico Rangel Filho; Patrícia Gadelha; Ana Carolina Thé; George Robson Ibiapina; Barbara Sales Gomes; Vera Santos; Maíra Melo da Fonseca; Karoline Frasão Viana; Isis Gabriella Lopes; Douglas Araújo; Luciana Naves
Journal:  Int J Endocrinol       Date:  2016-02-29       Impact factor: 3.257

10.  Behavioral and steroidogenic pharmacology of phenyl ring substituted etomidate analogs in rats.

Authors:  Megan McGrath; Alissa Hofmann; Douglas E Raines
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-05       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.